EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The impact of PD-L1 expression status on the prognosis of ALK-positive lung cancer patients

Li Wang, Yingjun Kong, Yao Zhang, Chuanyong Mu

Cancer Treatment and Research Communications · 2024

DOI: 10.1016/j.ctarc.2025.100868 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2024. Verfasst von Li Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, China. Hauptthemen laut MEDLINE: Activin Receptors, Type II, Lung Neoplasms, B7-H1 Antigen, Gene Expression. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: This study analyzes the clinical characteristics of ALK-positive lung cancer patients and the impact of PD-L1 expression on their prognosis, providing insights for diagnosis and treatment. MATERIALS AND METHODS: A total of 291 ALK-positive lung cancer patients, tested for PD-L1 expression at the First Affiliated Hospital of Soochow University between January 2019 and November 2021, were included. Clinical data and prognostic information were collected. Statistical analysis was conducted using SPSS 26.0 to explore the relationship between clinical features and prognosis. RESULTS: In ALK positive patients, the PD-L1 positivity rate was 59.8 %, with 19.2 % showing strong positivity. PD-L1 positive patients were predominantly male, over 55 years old, and presented more clinical symptoms, higher Ki-67 expression, larger tumor sizes, and more advanced disease stages. The progression-free survival (PFS) and overall survival (OS) were significantly lower in the ALK+PD-L1+ group compared to the ALK+PD-L1- group. Those receiving targeted therapy in stage IIIB-IVB non-squamous non-small cell lung cancer had significantly higher PFS and OS. CONCLUSION: PD-L1 positivity is common in ALK-positive lung cancer patients and correlates with poorer prognosis. PD-L1 serves as an independent predictor of adverse outcomes, indicating its potential as a biomarker for assessing lung cancer severity and prognosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Activin Receptors, Type IILung NeoplasmsB7-H1 AntigenGene ExpressionPrognosisBiomarkers, TumorProgression-Free SurvivalRetrospective StudiesCarcinoma, Non-Small-Cell LungHumansMaleFemaleMiddle AgedKaplan-Meier EstimateAntineoplastic AgentsMolecular Targeted TherapyYoung AdultAdultAgedAged, 80 and over

Stichwörter der Autor:innen

ALK gene mutationClinical characteristicsNon-squamous non-small cell lung cancerPD-L1Prognosis

Substanzen

ACVRL1 protein, humanActivin Receptors, Type IICD274 protein, humanB7-H1 AntigenBiomarkers, TumorAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, China.
  • Department of Respiratory Medicine, Pingshan District Central Hospital of Shenzhen, Guangdong, 518122, China.
  • Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, China. Electronic address: mcy028@126.com.

Zitieren

APA

Wang, L., Kong, Y., Zhang, Y., & Mu, C. (2024). The impact of PD-L1 expression status on the prognosis of ALK-positive lung cancer patients. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2025.100868

Vancouver

Wang L, Kong Y, Zhang Y, Mu C. The impact of PD-L1 expression status on the prognosis of ALK-positive lung cancer patients. Cancer Treatment and Research Communications. 2024. doi:10.1016/j.ctarc.2025.100868

BibTeX
@article{Wang2024,
  author = {Wang, Li and Kong, Yingjun and Zhang, Yao and Mu, Chuanyong},
  title = {The impact of PD-L1 expression status on the prognosis of ALK-positive lung cancer patients},
  journal = {Cancer Treatment and Research Communications},
  year = {2024},
  doi = {10.1016/j.ctarc.2025.100868}
}
Kostenlos starten →